{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:11:36Z","timestamp":1794877896506,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized the management of cancer patients, but the emergence of ICI-related endocrinopathies (IREs) has introduced new clinical challenges. Despite worldwide recognition of these adverse effects, data from the Middle East is scarce.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective-observational study included adult cancer patients who received at least one dose of ICI between January 2015 and January 2023. Descriptive statistics and multivariable regression (MVR) models were applied to delineate the incidence and clinical impact of IREs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median age of 649 included patients was 55 years, with male preponderance (70.7%). The incidence of IREs was 26.7%, dominated by primary hypothyroidism (62.4%), insulin deficiency (15%), and primary hyperthyroidism (13.9%). Pembrolizumab (62%) was the most utilized ICI among the study cohort, followed by nivolumab (23.7%), atezolizumab (12.5%), durvalumab (0.9%), avelumab (0.6%) and ipilimumab (0.1%). The mortality rates in the cohort and the IRE subgroup were 43.4% and 42.2%. MVR revealed age (OR 1.02, 95% CI (1.003\u20131.03), <jats:italic>P<\/jats:italic>\u2009=\u20090.02), pre-ICI white-cell (WBC) count (OR 0.94, 95% CI (0.89\u20130.99), <jats:italic>P<\/jats:italic>\u2009=\u20090.04), pembrolizumab (OR 2.6, 95% CI (1.05\u20136.3), <jats:italic>P<\/jats:italic>\u2009=\u20090.04), and nivolumab use (OR 2.6, 95% CI (1.04\u20136.6), <jats:italic>P<\/jats:italic>\u2009=\u20090.04) as significant predictors of IREs. After MVR, factors influencing mortality in the subgroup with IREs included a higher age (OR 1.1, 95% CI 1.04\u20131.2, <jats:italic>P<\/jats:italic>\u2009=\u20090.001) and platelet-to-lymphocyte ratio (OR 1.004, 95% CI 0.7\u20131.4, <jats:italic>P<\/jats:italic>\u2009=\u20090.006).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This first extensive Middle Eastern and South Asian cohort reported a higher-than-previously known incidence of IREs. Hypothyroidism, insulin deficiency, and hyperthyroidism were the commonest IREs, with pembrolizumab being the commonest ICI. IRE development was associated with higher age, a low WBC count, pembrolizumab, and nivolumab use. The development of IREs did not seem to influence mortality. Further research on IREs is imperative to optimize management guidelines in the era of precision medicine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-024-03812-2","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T18:12:07Z","timestamp":1734545527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7121-8574","authenticated-orcid":false,"given":"Fateen","family":"Ata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel Ahmad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Algorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr Faisal Musaed","family":"Alsharafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham Abo","family":"Shdid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Nofal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman R.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loai","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil Youssef El","family":"Annan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tareq Emad Hawash","family":"Al-Bkoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kakil Ibrahim","family":"Rasul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Elhadd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haval","family":"Surchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"3812_CR1","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","volume":"10","author":"P Dobosz","year":"2019","unstructured":"Dobosz P, Dzieci\u0105tkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019;10:2965.","journal-title":"Front Immunol"},{"issue":"7","key":"3812_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17(7):389\u201399.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"3812_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"3812_CR4","doi-asserted-by":"crossref","unstructured":"Gu Y-M, Shang Q-X, Zhuo Y, Zhou J-F, Liu B-W, Wang W-P, et al. Efficacy and safety of immune checkpoint inhibitor in advanced esophageal squamous cell carcinoma: a meta-analysis. Front Oncol. 2021;11.","DOI":"10.3389\/fonc.2021.777686"},{"issue":"1","key":"3812_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1186\/s12885-023-11285-4","volume":"23","author":"W Chen","year":"2023","unstructured":"Chen W, Chen J, Zhang L, Cheng S, Yu J. Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression \u2265 50%. BMC Cancer. 2023;23(1):791.","journal-title":"BMC Cancer"},{"key":"3812_CR6","doi-asserted-by":"publisher","first-page":"S1180","DOI":"10.1016\/j.annonc.2021.08.1659","volume":"32","author":"A Boutros","year":"2021","unstructured":"Boutros A, Bruzzone M, Tanda ET, Croce E, Arecco L, Cecchi F, et al. 1687P Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomized controlled trials: a systematic review and meta-analysis. Ann Oncol. 2021;32:S1180\u20131.","journal-title":"Ann Oncol"},{"issue":"6","key":"3812_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djab171","volume":"114","author":"BD Gonzalez","year":"2022","unstructured":"Gonzalez BD, Eisel SL, Bowles KE, Hoogland AI, James BW, Small BJ, et al. Meta-analysis of quality of life in cancer patients treated with immune checkpoint inhibitors. J Natl Cancer Inst. 2022;114(6):808\u201318.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"3812_CR8","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/j.jid.2019.03.656","volume":"139","author":"B Ly","year":"2019","unstructured":"Ly B, Walocko F, Chen SC, Yeung H. 580 Health-related quality of life measures and immune checkpoint inhibitors: a systematic review. J Invest Dermatol. 2019;139(5):S100.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"3812_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40261-023-01254-x","volume":"43","author":"YE Shin","year":"2023","unstructured":"Shin YE, Kumar A, Guo JJ. Spending, utilization, and price trends for immune checkpoint inhibitors in US Medicaid programs: an empirical analysis from 2011 to 2021. Clin Drug Investig. 2023;43(4):289\u201398.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"3812_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"3812_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eprac.2022.04.010","volume":"28","author":"KCJ Yuen","year":"2022","unstructured":"Yuen KCJ, Samson SL, Bancos I, Gosmanov AR, Jasim S, Fecher LA, et al. American Association of Clinical Endocrinology Disease State Clinical Review: evaluation and management of immune checkpoint inhibitor-mediated endocrinopathies: a practical case-based clinical approach. Endocr Pract. 2022;28(7):719\u201331.","journal-title":"Endocr Pract"},{"key":"3812_CR12","doi-asserted-by":"publisher","first-page":"ix29","DOI":"10.1093\/annonc\/mdx564","volume":"28","author":"A Shimatsu","year":"2017","unstructured":"Shimatsu A. Immune-related endocrinopathies during immune checkpoint blockade. Ann Oncol. 2017;28:ix29.","journal-title":"Ann Oncol."},{"issue":"1","key":"3812_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2478\/jtim-2022-0009","volume":"10","author":"D Lu","year":"2022","unstructured":"Lu D, Gao Y. Immune checkpoint inhibitor-related endocrinopathies. J Transl Int Med. 2022;10(1):9\u201314.","journal-title":"J Transl Int Med"},{"key":"3812_CR14","first-page":"119","volume-title":"SITC\u2019s Guide to Managing Immunotherapy Toxicity","author":"R Sharma","year":"2019","unstructured":"Sharma R, Nguyen H, Dadu R. Immune-related endocrinopathies associated with immune checkpoint inhibitors. In: Ernstoff MS, Puzanov I, Robert C, Diab A, Hersey P, editors. SITC\u2019s Guide to Managing Immunotherapy Toxicity. New York: Springer Publishing Company; 2019. p. 119\u201332."},{"issue":"7","key":"3812_CR15","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.ajpath.2016.02.023","volume":"186","author":"BV Chakravarthi","year":"2016","unstructured":"Chakravarthi BV, Nepal S, Varambally S. Genomic and epigenomic alterations in cancer. Am J Pathol. 2016;186(7):1724\u201335.","journal-title":"Am J Pathol"},{"issue":"2","key":"3812_CR16","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S1470-2045(20)30740-3","volume":"22","author":"S Briggs","year":"2021","unstructured":"Briggs S, Cavet J, Lamb C, Lightowlers S. Cancer and climate change: the environmental impact of cancer care. Lancet Oncol. 2021;22(2): e38.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3812_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s40495-017-0088-z","volume":"3","author":"NJW Rattray","year":"2017","unstructured":"Rattray NJW, Charkoftaki G, Rattray Z, Hansen JE, Vasiliou V, Johnson CH. Environmental influences in the etiology of colorectal cancer: the premise of metabolomics. Curr Pharmacol Rep. 2017;3(3):114\u201325.","journal-title":"Curr Pharmacol Rep"},{"issue":"8","key":"3812_CR18","first-page":"e44296","volume":"15","author":"A Alqahtani","year":"2023","unstructured":"Alqahtani A, Alghamdi L, Alghassab A, Almalki M. Immune checkpoint inhibitor-induced endocrine adverse events in cancer patients at a tertiary care center in Saudi Arabia. Cureus. 2023;15(8): e44296.","journal-title":"Cureus"},{"issue":"8","key":"3812_CR19","first-page":"002756","volume":"8","author":"AO Saleh","year":"2021","unstructured":"Saleh AO, Taha R, Mohamed SFA, Bashir M. Hyperosmolar hyperglycaemic state and diabetic ketoacidosis in nivolumab-induced insulin-dependent diabetes mellitus. Eur J Case Rep Intern Med. 2021;8(8): 002756.","journal-title":"Eur J Case Rep Intern Med"},{"key":"3812_CR20","doi-asserted-by":"crossref","unstructured":"Okura N, Asano M, Uchino J, Morimoto Y, Iwasaku M, Kaneko Y, et al. Endocrinopathies associated with immune checkpoint inhibitor cancer treatment: a review. J Clin Med. 2020;9(7).","DOI":"10.3390\/jcm9072033"},{"issue":"7","key":"3812_CR21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.cllc.2023.05.006","volume":"24","author":"WY Aung","year":"2023","unstructured":"Aung WY, Lee CS, Morales J, Rahman H, Seetharamu N. Safety and efficacy of immune checkpoint inhibitors in cancer patients and preexisting autoimmune disease: a systematic review and meta-analysis in non-small-cell lung cancer. Clin Lung Cancer. 2023;24(7):598\u2013612.","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"3812_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jemermed.2021.02.020","volume":"61","author":"T Knight","year":"2021","unstructured":"Knight T, Cooksley T. Emergency presentations of immune checkpoint inhibitor-related endocrinopathies. J Emerg Med. 2021;61(2):140\u20136.","journal-title":"J Emerg Med"},{"issue":"4","key":"3812_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13181-021-00833-8","volume":"17","author":"N Chhabra","year":"2021","unstructured":"Chhabra N, Kennedy J. A review of cancer immunotherapy toxicity: immune checkpoint inhibitors. J Med Toxicol. 2021;17(4):411\u201324.","journal-title":"J Med Toxicol"},{"issue":"1","key":"3812_CR24","doi-asserted-by":"publisher","first-page":"14039","DOI":"10.1038\/s41598-019-50574-6","volume":"9","author":"Y Eun","year":"2019","unstructured":"Eun Y, Kim IY, Sun J-M, Lee J, Cha H-S, Koh E-M, et al. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep. 2019;9(1):14039.","journal-title":"Sci Rep"},{"issue":"12","key":"3812_CR25","doi-asserted-by":"publisher","first-page":"e0144","DOI":"10.1097\/MD.0000000000010144","volume":"97","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Lu J-J, Du Y-P, Feng C-X, Wang L-Q, Chen M-B. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer. Medicine (Baltimore). 2018;97(12): e0144.","journal-title":"Medicine (Baltimore)"},{"issue":"Pt A","key":"3812_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pnpbp.2018.03.012","volume":"84","author":"MG Mazza","year":"2018","unstructured":"Mazza MG, Lucchi S, Tringali AGM, Rossetti A, Botti ER, Clerici M. Neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio in mood disorders: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2018;84(Pt A):229\u201336.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"3812_CR27","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/s41598-022-05400-x","volume":"12","author":"S Takayasu","year":"2022","unstructured":"Takayasu S, Mizushiri S, Watanuki Y, Yamagata S, Usutani M, Nakada Y, et al. Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study. Sci Rep. 2022;12(1):1294.","journal-title":"Sci Rep"},{"issue":"11","key":"3812_CR28","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99(11):4078\u201385.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"3812_CR29","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/imj.12819","volume":"45","author":"T Lam","year":"2015","unstructured":"Lam T, Chan MM, Sweeting AN, De Sousa SM, Clements A, Carlino MS, et al. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series. Intern Med J. 2015;45(10):1066\u201373.","journal-title":"Intern Med J"},{"issue":"4","key":"3812_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5694\/mja14.00803","volume":"201","author":"SM De Sousa","year":"2014","unstructured":"De Sousa SM, Long GV, Tonks KT. Ipilimumab-induced hypophysitis: early Australian experience. Med J Aust. 2014;201(4):198\u20139.","journal-title":"Med J Aust"},{"issue":"11","key":"3812_CR31","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40618-015-0301-z","volume":"38","author":"PB Araujo","year":"2015","unstructured":"Araujo PB, Coelho MC, Arruda M, Gadelha MR, Neto LV. Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Invest. 2015;38(11):1159\u201366.","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"3812_CR32","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11102-019-00978-4","volume":"22","author":"T Snyders","year":"2019","unstructured":"Snyders T, Chakos D, Swami U, Latour E, Chen Y, Fleseriu M, et al. Ipilimumab-induced hypophysitis, a single academic center experience. Pituitary. 2019;22(5):488\u201396.","journal-title":"Pituitary"},{"issue":"3","key":"3812_CR33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s12020-017-1289-2","volume":"58","author":"L Brilli","year":"2017","unstructured":"Brilli L, Danielli R, Ciuoli C, Calabr\u00f2 L, Di Giacomo AM, Cerase A, et al. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine. 2017;58(3):535\u201341.","journal-title":"Endocrine"},{"issue":"6","key":"3812_CR34","doi-asserted-by":"publisher","first-page":"e000654","DOI":"10.20945\/2359-3997000000654","volume":"67","author":"M Ornelas","year":"2023","unstructured":"Ornelas M, Borges-Canha M, Gouveia P, Ferreira M, Resende E, S\u00e1 M, et al. Immune checkpoint inhibitor-induced endocrinopathies: a possible indicator of improved survival. Arch Endocrinol Metab. 2023;67(6): e000654.","journal-title":"Arch Endocrinol Metab"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03812-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03812-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03812-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T19:09:00Z","timestamp":1734548940000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03812-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3812"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03812-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"21 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work is original and has not been and is not under consideration for publication in any other journal. The study was conducted in full compliance with the principles of the \u201cDeclaration of Helsinki,\u201d Good Clinical Practice (GCP), and other relevant guidelines. The study protocol was approved by the institutional review board (IRB) of the Medical Research Center (MRC) in Qatar (MRC-01\u201323-001). The IRB at the Medical Research Center (MRC), Hamad Medical Corporation, Qatar, waived the need for informed consent, considering the retrospective nature of the data review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The corresponding author (Fateen Ata) is an associate editor for BMC European Journal of Medical Research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"588"}}